PRIME-XS has ended

Sunday, 01 February 2015 00:00


PRIME-XS is finished. After four wonderful, exciting years, the PRIME-XS project has finally come to an end.
Up until January 2015, which marks the end of the project, a total of 145 user projects had been submitted. Of these projects, 122 were approved by external reviewers. These projects have come from 23 different European countries, indicative of the established reputation of PRIME-XS throughout Europe. In total, PRIME-XS has provided 2262.8 “days of access” to users throughout Europe and as of January 2015, well more than the originally expected 1971 access days, showing the clear need for access to proteomics facilities in Europe.

The European proteomics community and research has clearly being strengthened by the PRIME-XS consortium and its links with ESFRI projects such as Instruct, ELIXIR and Euro-Bioimaging, and other EU funded projects such as ProteomeXchange. Encouragingly, significant national investments in several EU member states in proteomics in recent years (e.g., The Netherlands and France) have confirmed the recognition of proteomics as a vital technology for biomedical research and helped towards the goal of achieving a sustainable future for European proteomics infrastructures.


That recognition, combined with the very positive feedback PRIME-XS received from its users and the potential for new scientific breakthroughs provided by the research activities in PRIME-XS, means the PRIME-XS community sees a positive future for proteomics in Europe and is making efforts to continue some of the activities also beyond the lifetime of the project.